Indefinite Delivery Contract SPE2DX15D9903

This is a single-award Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

The contract does not have any set-aside designations, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains. Under this IDC, the DLA has issued numerous delivery orders for a variety of pharmaceutical products, such as Norepinephrine Bitartrate, Metoprolol Tartrate, Phenylephrine Hydrochloride, Naloxone Hydrochloride, Lidocaine Hydrochloride, Pralidoxime Chloride, Amiodarone Tablets, Isoniazid Tablets, Etomidate Injection, Chloroquine Phosphate, and Bacitracin Ointment, among others. The delivery orders are predominantly awarded as firm fixed-price contracts with a total ceiling value of $4,999,999 and a place of performance at DMS Pharmaceutical Group's facility in Park Ridge, Illinois.